Hyaluronic Acid-Coated Silver Nanoparticles As a Nanoplatform for in Vivo Imaging Applications

Zhang, Xin; Yao, Mengfei; Chen, Muhua; Li, Liqiang; Dong, Chengyan; Hou, Yi; Zhao, Hang; Jia, Bing; Wang, Fan

doi:10.1021/acsami.6b08166

Cited by 40 publications

(36 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since silver nanoparticles were previously shown to have CT attenuation properties, we expected similar results from AION. 20, 39 We evaluated the CT contrast properties of AION using a clinical CT imaging system. A CT phantom image of the different agents is presented in Fig.…”

Section: Resultsmentioning

confidence: 99%

An all-in-one nanoparticle (AION) contrast agent for breast cancer screening with DEM-CT-MRI-NIRF imaging

et al. 2018

View full text Add to dashboard Cite

Conventional X-ray mammography has low diagnostic sensitivity for women with dense breasts. As a result, alternative contrast-enhanced screening tools such as dual energy mammography (DEM), computed tomography (CT), magnetic resonance imaging (MRI), and near-infrared fluorescence (NIRF) imaging are being used or investigated for these women. However, currently available contrast agents are non-ideal, have safety issues, and each imaging technique requires a different contrast agent. We therefore sought to develop a multimodal contrast agent that is functional for each breast imaging modality to simplify the diagnosis process and address the issues of existing contrast agents. Herein, we present a novel "all-in-one" nanoparticle (AION) multimodal imaging probe that has potent DEM, CT, MRI, and NIRF contrast properties and improved biocompatibility. AION were formed by co-encapsulation of a near-infrared fluorophore (DiR), silver sulfide nanoparticles (Ag2S-NP), and iron oxide nanoparticles (IO-NP) in PEGylated micelles. AION showed negligible cytotoxicity, which was in agreement with its minimal silver ion release profiles. AION generated strong contrast with all imaging modalities as demonstrated in phantom imaging. AION allowed in vivo tumor imaging as evidenced by the increase in contrast after injection. This study indicates the potential of AION as an effective multimodal contrast agent for breast cancer diagnosis with a range of imaging methods.

show abstract

Section: Resultsmentioning

confidence: 99%

An all-in-one nanoparticle (AION) contrast agent for breast cancer screening with DEM-CT-MRI-NIRF imaging

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Since HA has available functional groups such as hydroxyl, aldehyde, and carboxylic acid groups for chemical modifications, a diverse array of HA‐based nanomaterials is possible for biomedical applications . Recent studies have explored the use of HA as a coating material on the surface of silver nanoparticles (AgNPs), upconversion nanoparticles (UCNPs), gold nanoparticles (AuNPs), and mesoporous silica nanoparticles (MSNPs) for targeted imaging and therapy . For instance, a rapid and straightforward chemical‐reduction method enables the synthesis of HA‐coated AgNPs for X‐ray computed tomography and single‐photon‐emission computed tomography (SPECT) imaging .…”

Section: Stimuli‐responsive Nanomaterials Based On Hyaluronic Acidmentioning

confidence: 99%

“…Recent studies have explored the use of HA as a coating material on the surface of silver nanoparticles (AgNPs), upconversion nanoparticles (UCNPs), gold nanoparticles (AuNPs), and mesoporous silica nanoparticles (MSNPs) for targeted imaging and therapy . For instance, a rapid and straightforward chemical‐reduction method enables the synthesis of HA‐coated AgNPs for X‐ray computed tomography and single‐photon‐emission computed tomography (SPECT) imaging . By reacting the carboxyl groups on the HA backbone with AgNO 3 in the presence of sodium borohydride, the Ag + complexes rapidly reduce into spherical, ultrasmall AgNPs.…”

Section: Stimuli‐responsive Nanomaterials Based On Hyaluronic Acidmentioning

confidence: 99%

Hyaluronic Acid–Based Activatable Nanomaterials for Stimuli‐Responsive Imaging and Therapeutics: Beyond CD44‐Mediated Drug Delivery

et al. 2019

View full text Add to dashboard Cite

There is a rapidly increasing interest in developing stimuli-responsive nanomaterials for treating a variety of diseases. By enabling the activation of function locally at the sites of interest, it is possible to increase therapeutic efficacy significantly while simultaneously reducing adverse side effects. While there are many sophisticated nanomaterials available, they are often highly complex and not easily transferrable to industrial scales and clinical settings. However, nanomaterials based on hyaluronic acid offer a compelling strategy for reducing their complexity while retaining several desirable benefits such as active targeting and stimuli-responsive degradation. Herein, the basic properties of hyaluronic acid, its binding partners, and natural routes for degradation by hyaluronidases-hyaluronic-aciddegrading enzymes-and oxidative stresses are discussed. Recent advances in designing hyaluronic acid-based, actively targeted, hyaluronidase-or reactive-oxygen-species-responsive nanomaterials for both diagnostic imaging and therapeutic delivery, which go beyond merely the classical targeting of CD44, are summarized.

show abstract

“…Similarly constructed 99m Tc‐labeled AuNPs were also reported for cancer imaging via SPECT when conjugated with specific ligands to target gastrin‐releasing peptide receptors (GRP‐r) and alpha‐v‐beta‐3 integrin (α v β 3 ) (Mendoza‐Sánchez et al, 2010; Morales‐Avila et al, 2011). Recently, the first silver‐based SPECT imaging nanoprobe was reported using this HYNIC approach for 99m Tc‐labeling of AgNPs (X. Zhang, Yao, et al, 2016).…”

Section: Radiolabeling Of Mnpsmentioning

confidence: 99%

Radiolabeling strategies and pharmacokinetic studies for metal based nanotheranostics

Bahadori

Mulgaonkar

Hart

et al. 2020

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Radiolabeled metal‐based nanoparticles (MNPs) have drawn considerable attention in the fields of nuclear medicine and molecular imaging, drug delivery, and radiation therapy, given the fact that they can be potentially used as diagnostic imaging and/or therapeutic agents, or even as theranostic combinations. Here, we present a systematic review on recent advances in the design and synthesis of MNPs with major focuses on their radiolabeling strategies and the determinants of their in vivo pharmacokinetics, and together how their intended applications would be impacted. For clarification, we categorize all reported radiolabeling strategies for MNPs into indirect and direct approaches. While indirect labeling simply refers to the use of bifunctional chelators or prosthetic groups conjugated to MNPs for post‐synthesis labeling with radionuclides, we found that many practical direct labeling methodologies have been developed to incorporate radionuclides into the MNP core without using extra reagents, including chemisorption, radiochemical doping, hadronic bombardment, encapsulation, and isotope or cation exchange. From the perspective of practical use, a few relevant examples are presented and discussed in terms of their pros and cons. We further reviewed the determinants of in vivo pharmacokinetic parameters of MNPs, including factors influencing their in vivo absorption, distribution, metabolism, and elimination, and discussed the challenges and opportunities in the development of radiolabeled MNPs for in vivo biomedical applications. Taken together, we believe the cumulative advancement summarized in this review would provide a general guidance in the field for design and synthesis of radiolabeled MNPs towards practical realization of their much desired theranostic capabilities. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Diagnostic Tools > Diagnostic Nanodevices Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

Hyaluronic Acid-Coated Silver Nanoparticles As a Nanoplatform for in Vivo Imaging Applications

Cited by 40 publications

References 30 publications

An all-in-one nanoparticle (AION) contrast agent for breast cancer screening with DEM-CT-MRI-NIRF imaging

An all-in-one nanoparticle (AION) contrast agent for breast cancer screening with DEM-CT-MRI-NIRF imaging

Hyaluronic Acid–Based Activatable Nanomaterials for Stimuli‐Responsive Imaging and Therapeutics: Beyond CD44‐Mediated Drug Delivery

Radiolabeling strategies and pharmacokinetic studies for metal based nanotheranostics

Contact Info

Product

Resources

About